| pubmed-article:12684749 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12684749 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:12684749 | lifeskim:mentions | umls-concept:C0567416 | lld:lifeskim |
| pubmed-article:12684749 | lifeskim:mentions | umls-concept:C0019721 | lld:lifeskim |
| pubmed-article:12684749 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:12684749 | lifeskim:mentions | umls-concept:C0033362 | lld:lifeskim |
| pubmed-article:12684749 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
| pubmed-article:12684749 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:12684749 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:12684749 | pubmed:dateCreated | 2003-5-9 | lld:pubmed |
| pubmed-article:12684749 | pubmed:abstractText | Presentation of peptide epitopes derived from beta-cell autoantigens, such as insulin and its precursor molecules, by MHC class II molecules to autoreactive T-cells is believed to play a role in the development of Type 1 diabetes. However, little is known about the interaction between peptides of (prepro)insulin and MHC class II molecules permissive and protective for Type 1 diabetes. In this study therefore, peptides spanning the human preproinsulin sequence were assessed for their binding characteristics to Type 1 diabetes-protective and -permissive HLA molecules. | lld:pubmed |
| pubmed-article:12684749 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12684749 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12684749 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12684749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12684749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12684749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12684749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12684749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12684749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12684749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12684749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12684749 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12684749 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:12684749 | pubmed:issn | 0012-186X | lld:pubmed |
| pubmed-article:12684749 | pubmed:author | pubmed-author:EllisR JRJ | lld:pubmed |
| pubmed-article:12684749 | pubmed:author | pubmed-author:ArifSS | lld:pubmed |
| pubmed-article:12684749 | pubmed:author | pubmed-author:PeakmanMM | lld:pubmed |
| pubmed-article:12684749 | pubmed:author | pubmed-author:AstillT PTP | lld:pubmed |
| pubmed-article:12684749 | pubmed:author | pubmed-author:TreeT I MTI | lld:pubmed |
| pubmed-article:12684749 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12684749 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:12684749 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12684749 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12684749 | pubmed:pagination | 496-503 | lld:pubmed |
| pubmed-article:12684749 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:12684749 | pubmed:meshHeading | pubmed-meshheading:12684749... | lld:pubmed |
| pubmed-article:12684749 | pubmed:meshHeading | pubmed-meshheading:12684749... | lld:pubmed |
| pubmed-article:12684749 | pubmed:meshHeading | pubmed-meshheading:12684749... | lld:pubmed |
| pubmed-article:12684749 | pubmed:meshHeading | pubmed-meshheading:12684749... | lld:pubmed |
| pubmed-article:12684749 | pubmed:meshHeading | pubmed-meshheading:12684749... | lld:pubmed |
| pubmed-article:12684749 | pubmed:meshHeading | pubmed-meshheading:12684749... | lld:pubmed |
| pubmed-article:12684749 | pubmed:meshHeading | pubmed-meshheading:12684749... | lld:pubmed |
| pubmed-article:12684749 | pubmed:meshHeading | pubmed-meshheading:12684749... | lld:pubmed |
| pubmed-article:12684749 | pubmed:meshHeading | pubmed-meshheading:12684749... | lld:pubmed |
| pubmed-article:12684749 | pubmed:meshHeading | pubmed-meshheading:12684749... | lld:pubmed |
| pubmed-article:12684749 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12684749 | pubmed:articleTitle | Promiscuous binding of proinsulin peptides to Type 1 diabetes-permissive and -protective HLA class II molecules. | lld:pubmed |
| pubmed-article:12684749 | pubmed:affiliation | Department of Immunology, Guy's, King's and St. Thomas' School of Medicine, 123 Coldharbour Lane, SE5 9NU, London, United Kingdom. | lld:pubmed |
| pubmed-article:12684749 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12684749 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12684749 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12684749 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12684749 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12684749 | lld:pubmed |
